Xenon Pharmaceuticals Inc
XENE
Market Cap$3.05B
Close$
$2.06
94.8% downside
Current Fair Value
94.8% downsideOvervalued by 94.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.05 Billion |
|---|---|
| Enterprise Value | $2.97 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-2.73 |
| Beta | 1.25 |
| Outstanding Shares | 77,926,205 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -14.59 |
|---|---|
| PEG | -49.35 |
| Price to Sales | - |
| Price to Book Ratio | 4.0 |
| Enterprise Value to Revenue | 551.66 |
| Enterprise Value to EBIT | -11.62 |
| Enterprise Value to Net Income | -14 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Xenon Pharmaceuticals Inc
CEO: Simon Pimstone